Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
ISSN: 2329-8790
Shipra Gandhi
Tanzania
Review Article
Brentuximab Vedotin and Diffuse Large B-cell Lymphoma
Author(s): Shipra Gandhi and Neha GuptaShipra Gandhi and Neha Gupta
Brentuximab Vedotin., an anti-CD30 antibody drug conjugate (ADC) received FDA approval in 2011 for the treatment of relapsed/refractory Hodgkin's lymphoma and anaplastic large cell lymphoma based on 100% CD30 expression. In this review, we have discussed the various trials of Brentuximab Vedotin.in diffuse large B-cell lymphoma. Brentuximab Vedotin.is an ADC of monoclonal antibody conjugated with Monomethyl Auristatin E (MMAE), a microtubule inhibitor and hence facilitates selective delivery of potent MMAE to only the CD30 positive cells avoiding any off-target side effects. CD30 has restricted expression in normal tissues. According to the current trials, there does not seem to be an association between the efficacy of Brentuximab Vedotin and CD30 expression levels. Prospective trials are required to test the efficacy of Brentuximab Vedotin in diffuse large B-cell lymphoma and ot.. View More»
DOI:
10.4172/2329-8790.1000183